The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509.
Yoshikazu Kotani
No relevant relationships to disclose
Miyako Satouchi
No relevant relationships to disclose
Masahiko Ando
No relevant relationships to disclose
Kazuhiko Nakagawa
No relevant relationships to disclose
Nobuyuki Yamamoto
No relevant relationships to disclose
Yukito Ichinose
No relevant relationships to disclose
Yuichiro Ohe
No relevant relationships to disclose
Makoto Nishio
No relevant relationships to disclose
Toyoaki Hida
No relevant relationships to disclose
Koji Takeda
No relevant relationships to disclose
Tatsuo Kimura
No relevant relationships to disclose
Koichi Minato
No relevant relationships to disclose
Akira Yokoyama
No relevant relationships to disclose
Shinji Atagi
No relevant relationships to disclose
Taro Shibata
No relevant relationships to disclose
Haruhiko Fukuda
No relevant relationships to disclose
Tomohide Tamura
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Taiho Pharmaceutical; Yakult
Nagahiro Saijo
No relevant relationships to disclose